|
Volumn 56, Issue 4, 2003, Pages 915-916
|
Has "MAID" made it in the management of high-risk soft-tissue sarcoma?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTHRACYCLINE;
DACARBAZINE;
DOXORUBICIN;
IFOSFAMIDE;
MESNA;
ADJUVANT CHEMOTHERAPY;
BONE MARROW DEPRESSION;
CANCER CHEMOTHERAPY;
CANCER MORTALITY;
CANCER RADIOTHERAPY;
CANCER RECURRENCE;
CANCER RISK;
CANCER SURGERY;
CANCER SURVIVAL;
CLINICAL PRACTICE;
CLINICAL TRIAL;
DESQUAMATION;
DISABILITY;
DISEASE CONTROL;
EDITORIAL;
FEBRILE NEUTROPENIA;
FIBROSIS;
GYNECOLOGIC DISEASE;
HIGH RISK PATIENT;
HISTOLOGY;
HOSPITALIZATION;
HUMAN;
LIMB TUMOR;
META ANALYSIS;
METASTASIS;
METHODOLOGY;
POSTOPERATIVE CARE;
PREOPERATIVE CARE;
PRIORITY JOURNAL;
RISK ASSESSMENT;
SOFT TISSUE CANCER;
STATISTICAL SIGNIFICANCE;
TELANGIECTASIA;
TOXICITY;
|
EID: 0038724924
PISSN: 03603016
EISSN: None
Source Type: Journal
DOI: 10.1016/S0360-3016(03)00185-8 Document Type: Editorial |
Times cited : (9)
|
References (9)
|